Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial - Behringer, Karolin; Goergen, Helen; Hitz, Felicitas (The lancet, 2015)
Online 22 December 2014